110032-65-0

Basic information

• Product Name: (S)-Lorazepam
• Synonyms: (S)-Lorazepam;2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-, (3S)- (9CI);2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-, (S)-;DIWRORZWFLOCLC-HNNXBMFYSA-N
• CAS NO: 110032-65-0
• Molecular Formula: C15H10Cl2N2O2
• Molecular Weight: 321.16
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 110032-65-0.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 533.8±50.0 °C(Predicted)
• Appearance: /
• Density: 1.52±0.1 g/cm3(Predicted)
• PKA: 10.80±0.70(Predicted)
• CAS DataBase Reference: (S)-Lorazepam(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-Lorazepam(110032-65-0)
• EPA Substance Registry System: (S)-Lorazepam(110032-65-0)

Safety Data

• Hazardous Substances Data: 110032-65-0(Hazardous Substances Data)

Usage

Uses

(S) enantiomer of Lorazepam (L469850).

Upstream product

• 89722-85-0 Trifluoro-acetic acid 7-chloro-5-(2-chloro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl ester 
• 848-75-9 lormetazepam 
• 2848-96-6 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-2-oxo-2H-1,4-benzodiazepin-3-yl acetate 
• 2955-37-5 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one-4-oxide 
• 125534-53-4 lorazepam acetone solvate 
• 2958-36-3 (2-amino-5-chloro-phenyl)-(2-chloro-phenyl)-methanone 
• 14405-03-9 2-chloroacetamido-2’,5-dichlorobenzophenone 
• 846-49-1 lorazepam 

Downstream Products

• 134051-36-8 Benzoic acid 7-chloro-5-(2-chloro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl ester 
• 18878-24-5 3-O-ethyllorazepam 
• 130753-96-7 2-Methyl-3-nitro-benzoic acid 7-chloro-5-(2-chloro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl ester 
• 71107-65-8 lorazepam-β-phenyl-propionate 
• 71107-66-9 lorazepam-α-methyl-β-phenyl-propionate 
• 4306-26-7 7-chloro-5-(2-chloro-phenyl)-1,3,4,5-tetrahydro-benzo[e][1,4]diazepin-2-one 
• 60628-58-2 3-Fluoro-7-chloro-5-(2-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one 
• 130754-08-4 (S)-2-(6-Methoxy-naphthalen-2-yl)-propionic acid (R)-7-chloro-5-(2-chloro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl ester 
• 130753-89-8 (S)-2-(6-Methoxy-naphthalen-2-yl)-propionic acid (S)-7-chloro-5-(2-chloro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl ester 
• 82384-75-6 (7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one)AuCl₃ 

Relevant articles and documents

Dynamic micellar electrokinetic chromatography. Determination of the enantiomerization barriers of oxazepam, temazepam, and lorazepam

The temperature-dependent enantiomerization barriers of oxazepam, temazepam, and lorazepam have been determined between 0 and 30 °C by dynamic micellar electrokinetic chromatography (DMEKC) in an aqueous 20 mM borate/phosphate buffer system at pH 8 with 6

Light-stabilized pharmaceutical composition, and preparation method and pharmaceutical application thereof

The invention relates to a light-stabilized pharmaceutical composition, and a preparation method and pharmaceutical application thereof. Specifically, the pharmaceutical composition comprises a lorazepam crystal and pharmaceutical adjuvants. The lorazepam crystal is radiated by Cu-K alpha. In a powder X-ray diffraction pattern expressed by an angle of 2 theta, there are diffraction peaks at approximately 12.17 degrees, approximately 14.15 degrees, approximately 15.27 degrees, approximately 16.84 degrees, approximately 17.91 degrees and approximately 20.81 degrees. For example, the crystal hasdiffraction peaks at approximately 7.93 degrees, approximately 9.04 degrees, approximately 12.17 degrees, approximately 14.15 degrees, approximately 15.27 degrees, approximately 16.84 degrees, approximately 17.91 degrees, approximately 20.81 degrees, approximately 21.44 degrees and approximately 26.38 degrees. A new crystal form and the pharmaceutical composition, which are used for preparing lorazepam and prepared by the method, exhibit excellent properties as described in the description of the invention.

Evaluation of the Edman degradation product of vancomycin bonded to core-shell particles as a new HPLC chiral stationary phase

A modified macrocyclic glycopeptide-based chiral stationary phase (CSP), prepared via Edman degradation of vancomycin, was evaluated as a chiral selector for the first time. Its applicability was compared with other macrocyclic glycopeptide-based CSPs: TeicoShell and VancoShell. In addition, another modified macrocyclic glycopeptide-based CSP, NicoShell, was further examined. Initial evaluation was focused on the complementary behavior with these glycopeptides. A screening procedure was used based on previous work for the enantiomeric separation of 50 chiral compounds including amino acids, pesticides, stimulants, and a variety of pharmaceuticals. Fast and efficient chiral separations resulted by using superficially porous (core-shell) particle supports. Overall, the vancomycin Edman degradation product (EDP) resembled TeicoShell with high enantioselectivity for acidic compounds in the polar ionic mode. The simultaneous enantiomeric separation of 5 racemic profens using liquid chromatography-mass spectrometry with EDP was performed in approximately 3?minutes. Other highlights include simultaneous liquid chromatography separations of rac-amphetamine and rac-methamphetamine with VancoShell, rac-pseudoephedrine and rac-ephedrine with NicoShell, and rac-dichlorprop and rac-haloxyfop with TeicoShell.